Healthcare utilization and economic costs of neurocognitive disorders in community-dwelling older Chinese adults: A comparison with 9 Asian economies

Abstract

Background

It is increasing recognized that care for people with neurocognitive disorders (NCDs) is costly, and cost of NCDs can be highly context dependent.

Objective

To evaluate the healthcare utilization and economic costs of NCDs in Hong Kong, cross referencing with other Asian metropolitan cities.

Methods

461 older adults aged ≥60 (major NCD: 68, mild NCD: 264, normal cognition: 129) were recruited from a population-based cross-sectional survey, Hong Kong Mental Morbidity Survey for Older People. Healthcare utilization was collected by Resource Utilization of Dementia. Per person cost was estimated from a societal perspective and expressed in 2022 US dollars. Cost-associative factors were explored. Our findings were compared to cost-of-illness evidence in major Asian metropolitan cities by a systematic review.

Results

Annual costs per community-living adult with mild and major NCD were US$5677 (95%CI: 4985–6465) and US$12,841 (9940–16,590) in Hong Kong. For those with major NCD, costs doubled in severer stages, and diagnosed cases incurred nearly 30% more costs than hidden cases. Dementia cost in Hong Kong was lower than other high-income Asian economies and mainland China, mainly due to methodological heterogeneities and lower utilization of social care services.

Conclusions

The great economic burden of NCDs in Hong Kong reflects a striking social and care needs, particularly in moderate and severe stages. Care planning should prepare for the blowout needs being revealed by hidden cases and the diversified needs by different stages and family caregivers. Region- and population-specific studies with rigor design are warranted to estimate cost-effectiveness of upcoming treatment strategies.

Keywords

Alzheimer's disease Asia cost of illness healthcare neurocognitive disorder

Get full access to this article

View all access options for this article.

References

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 2020; 396: 1204–1222.

Rice

. Cost of illness studies: what is good about them? Inj Prev 2000; 6: 177–179.

Wimo

Seeher

Cataldi

, et al. The worldwide costs of dementia in 2019. Alzheimers Dement 2023; 19: 2865–2873.

Mattap

Mohan

McGrattan

, et al. The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review. BMJ Glob Health 2022; 7: e007409.

Oremus

Aguilar

. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics 2011; 29: 141–156.

Schaller

Mauskopf

Kriza

, et al. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry 2015; 30: 111–129.

Michalowsky

Flessa

Eichler

, et al. Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial. Eur J Health Econ 2018; 19: 87–102.

Fillit

Hill

. The costs of vascular dementia: a comparison with Alzheimer's disease. J Neurol Sci 2002; 203–204: 35–39.

Martin

Ricci

Kotzan

, et al. The net cost of Alzheimer disease and related dementia: a population-based study of Georgia medicaid recipients. Alzheimer Dis Assoc Disord 2000; 14: 151–159.

10.

Jutkowitz

Kuntz

Dowd

, et al. Effects of cognition, function, and behavioral and psychological symptoms on out-of-pocket medical and nursing home expenditures and time spent caregiving for persons with dementia. Alzheimers Dement 2017; 13: 801–809.

11.

Deb

Thornton

Sambamoorthi

, et al. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 189–202.

12.

Deb

Sambamoorthi

Thornton

, et al. Direct medical expenditures associated with Alzheimer's and related dementias (ADRD) in a nationally representative sample of older adults – an excess cost approach. Aging Ment Health 2018; 22: 619–624.

13.

Lin

Zhong

Fillit

, et al. Medicare expenditures of individuals with Alzheimer's disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc 2016; 64: 1549–1557.

14.

Michalowsky

Eichler

Thyrian

, et al.

Healthcare resource utilization and cost in dementia: are there differences between patients screened positive for dementia with and those without a formal diagnosis of dementia in primary care in Germany?

Int Psychogeriatr 2016; 28: 359–369.

15.

Jia

Wei

Chen

, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018; 14: 483–491.

16.

Costa

Derumeaux

Rapp

, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2012; 2: 18.

17.

Wimo

Reed

Dodel

, et al. The GERAS study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries–study design and baseline findings. J Alzheimers Dis 2013; 36: 385–399.

18.

Census and Statistics Department. Hong Kong Population Projections 2020–2069, https://www.censtatd.gov.hk/en/scode190.html (2020, accessed 10 August 2024).

19.

Chau

McGhee

, et al. Trends in prevalence and mortality of dementia in elderly Hong Kong population: projections, disease burden, and implications for long-term care. Int J Alzheimers Dis 2012; 2012: 406852.

20.

Lam

Tam

Lui

, et al. Prevalence of very mild and mild dementia in community-dwelling older Chinese people in Hong Kong. Int Psychogeriatr 2008; 20: 135–148.

21.

Parmelee

Thuras

Katz

, et al. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130–137.

22.

Wimo

Gustavsson

Jonsson

, et al. Application of resource utilization in dementia (RUD) instrument in a global setting. Alzheimers Dement 2013; 9: 429–435 e417.

23.

Tarricone

. Cost-of-illness analysis. What room in health economics? Health Policy 2006; 77: 51–63.

24.

Woo

Thompson

Magadi

. Monetary cost of family caregiving for people with dementia in Singapore. Arch Gerontol Geriatr 2017; 71: 59–65.

25.

Census and Statistics Department. Thematic household survey report no. 63, https://www.statistics.gov.hk/pub/B11302632017XXXXB0100.pdf (2017, accessed 22 September 2024).

26.

Bloom

de Pouvourville

Straus

. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 2003; 43: 158–164.

27.

Malehi

Pourmotahari

Angali

. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ Rev 2015; 5: 11.

28.

Menard

Applied logistic regression analysis. Thousand Oaks, CA: Sage Publications, Inc., 2002, pp.11–14.

29.

Yan

Chen

, et al. Associated factors of total costs of Alzheimer's disease: a cluster-randomized observational study in China. J Alzheimers Dis 2019; 69: 795–806.

30.

Liao

Fan

, et al. The economic burden of Alzheimer's disease in zhejiang province. J Alzheimers Dis 2021; 80: 539–553.

31.

Guo

Meng

Zuo

, et al. Costs of dementia with Lewy bodies: a Chinese multicenter cross-sectional study. Int J Geriatr Psychiatry 2023; 38: e5848.

32.

Kuo

Lan

Chen

, et al. Dementia care costs and the patient's quality of life (QoL) in Taiwan: home versus institutional care services. Arch Gerontol Geriatr 2010; 51: 159–163.

33.

Pai

Shih

. Economic impact of dementia by disease severity: exploring the relationship between stage of dementia and cost of care in Taiwan. PLoS One 2016; 11: e0148779.

34.

Chang

Pai

, et al. Predictors of caregiver burden and care costs for older persons with dementia in Taiwan. Int Psychogeriatr 2019; 31: 885–894.

35.

Nakanishi

Igarashi

Ueda

, et al. Costs and resource use associated with community-dwelling patients with Alzheimer's disease in Japan: baseline results from the prospective observational GERAS-J study. J Alzheimers Dis 2020; 74: 127–138.

36.

Nakanishi

Igarashi

Ueda

, et al. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study. Curr Med Res Opin 2021; 37: 1331–1339.

37.

Abdin

Subramaniam

Achilla

, et al. The societal cost of dementia in Singapore: results from the WiSE study. J Alzheimers Dis 2016; 51: 439–449.

38.

Han

Lee

Cho

, et al. Socioeconomic costs of dementia based on utilization of health care and long-term-care services: a retrospective cohort study. Int J Environ Res Public Health 2021; 18: 376.

39.

Kongpakwattana

Dejthevaporn

Krairit

, et al. A real-world evidence analysis of associations among costs, quality of life, and disease-severity indicators of Alzheimer's disease in Thailand. Value Health 2019; 22: 1137–1145.

40.

Malapur

Kumar

Khandelwal

, et al. Cost of illness of major neurocognitive disorders in India. Neurol India 2021; 69: 1265–1268.

41.

Dominguez

Jiloca

Fowler

, et al. Dementia incidence, burden and cost of care: a Filipino community-based study. Front Public Health 2021; 9: 628700.

42.

Aajami

Kebriaeezadeh

Nikfar

. Direct and indirect cost of managing Alzheimer's disease in the Islamic Republic of Iran. Iran J Neurol 2019; 18: 7–12.

43.

Liu

. Economic costs of dementia in low and middle income countries. London, UK: King's College London, 2013.

44.

Hung

Walline

Chan

EYY

, et al. Health service utilization in Hong Kong during the COVID-19 pandemic – A cross-sectional public survey. Int J Health Policy Manag 2022; 11: 508–513.

45.

Xin

Wong

, et al. Hospitalizations and mortality during the first year of the COVID-19 pandemic in Hong Kong, China: an observational study. Lancet Reg Health West Pac 2023; 30: 100645.

46.

Wimo

Winblad

Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based study. Int Psychogeriatr 2003; 15(Suppl 1): 251–256.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB